PCK1 and melanoma: Compared with the A2058R+vemurafenib group, the A2058R+3-MPA+vemurafenib group showed a significant increase of ROS but a decrease in the number of tumor cells, which demonstrated that the inhibition of PCK1 sensitized melanoma to vemurafenib.